Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 13 of 116

  1. HCB-ONC002

    The George Institute

    HER2-positive early breast cancer

    phase 3 small molecule active

    1 trial

  2. HD201

    Prestige Biopharma Belgium

    HER2 Positive Breast Cancer

    phase 3 small molecule completed

    1 trial

  3. HIPEC with neoadjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  4. HLX02

    Shanghai Henlius Biotech

    Breast Cancer

    phase 3 mab completed

    1 trial

  5. HOVON 127 BL

    Wuhan Createrna Science and Technology Co., Ltd

    Burkitt lymphoma

    phase 3 small molecule active

    1 trial

  6. HQP1351AG301

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  7. HQP1351CG301

    Lacuna Pharma Pty Ltd

    Chronic Phase Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  8. HS-19-657

    Camurus Pty Ltd

    gastroenteropancreatic neuroendocrine tumors

    phase 3 small molecule active

    1 trial

  9. HVA

    The First People's Hospital of Lianyungang

    Newly Diagnosed Acute Myeloid Leukemia With High Risk

    phase 3 small molecule active

    1 trial

  10. Herceptin

    Hoffmann-La Roche

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  11. Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 3 other active

    1 trial

  12. I3Y-MC-JPCF

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  13. I3Y-MC-JPCM

    Eli Lilly Co.

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  14. I3Y-MC-JPEF

    Eli Lilly Co.

    Breast Neoplasm, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  15. IAC regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  16. IB2017-04

    The George Institute

    Resectable, non-metastatic soft-tissue sarcoma (STS)

    phase 3 small molecule active

    1 trial

  17. IBCSG 59-19

    Partner Therapeutics Limited

    Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer.

    phase 3 small molecule active

    1 trial

  18. ICM ADX-2191 injection

    Aldeyra Therapeutics

    Primary Vitreoretinal Lymphoma

    phase 3 small molecule active

    1 trial

  19. IDE196

    IDEAYA Biosciences

    Metastatic Uveal Melanoma

    phase 3 small molecule active

    2 trials

  20. IDE196 (LXS196), IDE196 (LXS196)

    IDEAYA Biosciences

    Uveal Melanoma

    phase 3 small molecule active

    1 trial

  21. IDE196-002

    IDEAYA Biosciences

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  22. IDE196-002

    IDEAYA Biosciences

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  23. IFCT-1701

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  24. IFCT-1805

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  25. IFCT-2103

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  26. IFOM-CPT0092022PO008

    Fondazione Telethon ETS

    Colon cancer

    phase 3 small molecule active

    1 trial

  27. IFx-Hu2.0

    TuHURA Biosciences, Inc./NV

    Advanced Or Metastatic Merkel Cell Carcinoma

    phase 3 small molecule active

    2 trials

  28. IJB-SHAPERS-ODN-013

    The George Institute

    locally advanced rectal cancer

    phase 3 small molecule active

    1 trial

  29. IM JZP-458

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia

    phase 3 small molecule completed

    1 trial

  30. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Wuhan Createrna Science and Technology Co., Ltd

    Small-cell lung cancer, extensive stage

    phase 3 small molecule active

    1 trial

  31. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  32. IMFINZI for Advanced Biliary Cancer (ABC)

    Ningbo Cancer Hospital

    Advanced Biliary Cancer (ABC)

    phase 3 small molecule active

    1 trial

  33. IMMU-132-13

    Gilead Sciences Pty Limited

    Locally Advanced or Metastatic Unresectable Urothelial Cancer

    phase 3 small molecule active

    1 trial

  34. INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  35. INBRX106-01-201

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  36. INCA033890-303

    Incyte

    Metastatic Microsatellite Stable Colorectal Cancer

    phase 3 small molecule active

    1 trial

  37. INCB 54828-302

    Incyte

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  38. INCB123667-305

    Incyte

    Ovarian cancer

    phase 3 small molecule active

    1 trial

  39. INCMGA 0012-304

    Incyte

    Metastatic nonsquamous or squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  40. INCMOR 0208-305

    Incyte

    Diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  41. INCMOR0208-301

    Incyte

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial

  42. INFLUENCE

    AXIM BIOTECHNOLOGIES, INC.

    B-cell Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial

  43. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Sarcoma,Soft Tissue

    phase 3 small molecule active

    1 trial

  44. IO102-IO103

    IO Biotech

    Metastatic Melanoma

    phase 3 small molecule active

    1 trial

  45. IOB-013/KN-D18

    IO Biotech

    Previously untreated, unresectable, or metastatic melanoma

    phase 3 small molecule active

    1 trial

  46. ION363-CS1

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations

    phase 3 small molecule active

    1 trial

  47. IOV-MEL-301

    Iovance Biotherapeutics B.V.

    Melanoma

    phase 3 small molecule active

    1 trial

  48. IP

    Solid Biosciences

    Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.